Blog

The AI Gap Isn’t Technology. It’s Talent.

Every life sciences and healthcare organization has an AI strategy.
Very few have the right leaders to execute it.

The tools are easy to buy.
The judgment isn’t.

In January, the FDA and EMA issued joint principles for AI in drug development: human oversight, risk-based use, and lifecycle management.

In healthcare, the Joint Commission and the Coalition for Health AI issued similar guidance on AI governance and monitoring.

Translation: AI in a regulated environment needs someone who owns it.

Someone who can defend it to an inspector.
Someone who knows when to reject what the model says.

That’s rarely a data scientist.
And rarely a traditional Research, Clinical or Product Development leader.

It’s the hybrid. And there aren’t many yet.

The organizations that find them first will move faster, with less risk.

That’s why Marcus & Associates added dedicated AI, Machine Learning, Data Science & Analytics recruiting for Life Sciences and Healthcare, across Research, Clinical, Medical, Product Development, Manufacturing, Supply Chain, Commercial and Enterprise Centers of Excellence.

Recent placements include:
• VP, Data Science – leading clinical diagnostics
• Sr Dir, Research Informatics – platform biotech
• Dir, AI Strategy – large pharma
• Principal Data Scientist – large cancer research hospital

https://lnkd.in/eYuP-Kzs

Who owns AI decisions in your regulated functions today?

Sources: FDA and EMA, Guiding Principles of Good AI Practice in Drug Development (January 2026); The Joint Commission and Coalition for Health AI, Guidance on the Responsible Use of AI in Healthcare (September 2025)

#lifesciences #healthcare #pharma #AI #datascience